Our Mission
Pipeline
Our Focus
We are advancing a wholly owned portfolio of oral small molecule GPCR-targeted programs focused initially on treating patients with significant unmet needs in endocrinology, immunology and inflammation, and metabolic disease.
For each program, we utilize our Native Complex Platform™ to discover a diverse portfolio of small molecules with mechanisms of action designed to have disease-modifying potential and with distinct chemical properties. We have prioritized programs that offer biomarker-driven strategies for early clinical readouts.
Pipeline
Scroll sideways to view more.
Program
Development Status
Program / Target
Mode of Action
Therapeutic Area
Indications
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3
PTH1R Program
Oral Small Molecule PTH1R Agonist for Hypoparathyroidism
22%
SEP-631 (MRGPRX2)
Oral Small Molecule MRGPRX2 NAM for CSU and Other Mast Cell Diseases
30%
TSHR Program
Oral Small Molecule TSHR NAM for Graves’ Disease and TED
15%
GLP-1R, GIPR, GCGR Program
Obesity, T2D and other metabolic diseases
15%
PTH1R = Parathyroid Hormone 1 Receptor
TSHR = Thyroid-Stimulating Hormone Receptor
MRGPRX2 = MAS-Related G Protein-Coupled Receptor X2
GLP-1R = Glucagon-Like Peptide 1 Receptor.
GIPR = Gastric Inhibitory Polypeptide Receptor
GCGR = Glucagon Receptor
The Details
Programs
Additional Information
PTH1R Program
Oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism that could offer a convenient, functional replacement for PTH for all hypoparathyroidism patients.
SEP-631 (MRGPRX2)
Oral small molecule negative allosteric modulator (NAM) that inhibits MRGPRX2 and could provide a differentiated treatment option for patients with chronic spontaneous urticaria (CSU) and other mast cell driven diseases.
TSHR Program
Oral small molecule thyroid-stimulating hormone receptor (TSHR) NAM that could offer a novel disease-modifying treatment approach for both Graves’ Disease and Thyroid Eye Disease.
GLP-1R, GIPR, GCGR Program
Novel, next-generation, oral small molecule single- or multi-acting agonists of the GLP-1, GIPR, glucagon receptors for patients with obesity, diabetes and other metabolic diseases.
